Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.59 |
| ▸ | PRKCA | P17252 | 1/20 | 0.59 |
| ▸ | TLR2 | O60603 | 4/20 | 0.57 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.56 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.56 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9206562 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNAPRKCEPRKCQPRKCD | |
| SCHEMBL9210754 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNAPRKCEPRKCQPRKCD | |
| SCHEMBL1101589 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNAPRKCEPRKCQPRKCD | |
| SCHEMBL1092063 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNAPRKCEPRKCQPRKCD | |
| SCHEMBL25474578 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNAPRKCEPRKCQPRKCD | |
| SCHEMBL20714687 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNAPRKCEPRKCQPRKCD | |
| SCHEMBL25474533 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNAPRKCEPRKCQPRKCD | |
| SCHEMBL23668333 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNAPRKCEPRKCQPRKCD | |
| SCHEMBL6375879 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNAPRKCEPRKCQPRKCD | |
| SCHEMBL18954214 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNAPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117545467-A | Nucleic acid-containing nanoparticles | 比奥-特里普公司 | 2024-02-09 | — | — | CN | disclosed |
| EP-2521711-B1 | QUATERNARY AMMONIUM SALT PRODRUGS | ALKERMES PHARMA IRELAND LTD (IE) | 2017-08-16 | — | — | EP | disclosed |
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011084849-A1 | DIARYLDIAZEPINE PRODRUGS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | NEOPHARM, INC. (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | SLC1A5, IDH1, ASS1 | ALDH1A1 74/4885LMNA 2321/4885PRKCE 4746/4885 |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | ALDH1A1 760/4885LMNA 3322/4885PRKCE 3868/4885 |
| US-20050266068-A1 | Cardiolipin molecules and methods of synthesis | PHOSPHO1, MGLL, LIPA | ALDH1A1 4029/4885LMNA 1174/4885PRKCE 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.